# A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07673029/  
OnCo record `nct07673029` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing GQ1005 in HER2-positive breast cancer, now recruiting.

## Summary

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07673029, led by GeneQuantum Healthcare (Suzhou), and recruiting on the registry. Official title: A Phase III, Multicenter, Open-label, Randomised Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane. Planned enrolment is 228 participants (estimated). The study started in 2025-01-10 and primary completion is expected in 2027-01-09. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07673029
- Phase: 3
- Setting: A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane
- Sponsor: GeneQuantum Healthcare (Suzhou)
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT07673029: https://clinicaltrials.gov/study/NCT07673029

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [GQ1005](https://onco.cc/drugs/gq1005/)
- companies: [GeneQuantum Healthcare (Suzhou)](https://onco.cc/companies/genequantum-healthcare-suzhou/)

---
JSON: https://onco.cc/api/v1/entities/nct07673029.json